Rise of AI Conference 2025 · Berlin · Applied AI Stage

The True Revolution Lies Ahead of Us

Ramin Assadollahi · Founder & CEO, ExB Group

At Rise of AI 2025 in Berlin, Ramin Assadollahi, founder and CEO of ExB Group, argues that AI is about to transform longevity and preventive medicine. He frames the goal as reaching a personal 'longevity escape velocity', where each medical advance extends lifespan long enough to reach the next one, referencing Aubrey de Grey's idea that the first 1,000-year-old may be only ten years younger than the first 150-year-old. He organizes longevity research into four systems: genes, the microbiome, the central nervous system and the immune system, which he calls a post-processor for the other three. He explains that conventional drug development costs up to 2.5 billion dollars and 10-15 years per drug, with under 11% of candidates reaching phase one trials, and proposes that AI-driven digital twins and in-silico simulation, an approach he compares to 'vibe coding', could make drug development interactive and personalized. He surveys wearables such as implantable EEGs, glucose-and-hydration sensors and sweat monitors as new sources of fast personal data, and closes by calling for a meta-framework linking simulations across biological levels and for changed legislation and data access to support personalized medicine.

Key takeaways

  • Assadollahi defines longevity escape velocity as each medical advance extending lifespan long enough to reach the next advance.
  • He organizes aging biology into four systems: genes, microbiome, central nervous system and immune system, with the immune system as the key post-processor.
  • Conventional drug development costs up to 2.5 billion dollars and 10-15 years, with under 11% of candidates reaching phase one trials.
  • Only about 16 digital twins of human organs exist today, including a Siemens heart model needing 12 hours to simulate one heartbeat.
  • He argues drug development needs an interactive, 'vibe coding'-style loop combining LLM-generated hypotheses with in-silico simulation of organs and cells.

Detailed notes

Longevity escape velocity

Assadollahi opens by reframing longevity not as avoiding death but as dying when one chooses, quoting Aubrey de Grey's claim that the first 1,000-year-old is likely only about 10 years younger than the first 150-year-old. He explains longevity escape velocity: every medical improvement should extend a person's remaining lifespan far enough to reach the next improvement. He lists the common longevity approaches: sleep, physical activity and nutrition (SPAN); supplements, citing Ray Kurzweil's reported 120 pills a day; body modification such as Brian Johnson's blood exchange with his son; and, without discussing it further, uploading personality and knowledge into an LLM copy of oneself.

Four systems that drive aging

He organizes the biology of aging into four systems: genes, which shape organ morphology and disease risk (for example the ApoE gene and Alzheimer's risk, identified through research on centenarians); the microbiome, roughly 100 trillion organisms split into neutral, beneficial and competitive groups, where competitive organisms increasingly dominate after about age 80 and weaken the immune system; the central nervous system, which shrinks and loses energy production with age, a process he connects to his own experience watching his father's seven-year decline with Alzheimer's; and the immune system, which he calls the most important of the four because it acts as a post-processor reacting to problems across the body, tied to the concept of 'inflammaging'.

Why drug development is broken, and digital twins as a fix

Assadollahi describes conventional drug development as costing 400-500 million dollars in the best case and around 2.5 billion dollars once failures are included, taking 10-15 years, with fewer than 11% of candidates reaching phase one because trials cannot easily target the right patient subgroups. He argues AI tools like 'the AI Scientist', an open-source system that generates and tests research ideas, are not yet used for drug discovery because biology cannot be fully simulated. He points to digital twins as the fix in progress: about 16 exist today, including a Siemens-built heart model that takes 12 hours of computation to simulate a single heartbeat at the cellular level, and argues hardware companies such as Dell, HP and Nvidia should invest in this space. He adds that personal genome sequencing now costs about 400 dollars and returns roughly 150 disease-predisposition reports, and highlights new fast-data wearables: Brainscape, an implantable 24/7 EEG he reviewed through a Swiss angel club; a Dexcom-Oura integration linking glucose and ring data; and sweat sensors reading metabolite data, alongside live AI monitoring of clinical ECG data that already alerts nurses in real time to save lives.

Vibe coding for drugs

Drawing an analogy to AI coding tools such as Bolt, Cursor and Replit, which mediate between a person's ideas and rigid, syntactically defined code, Assadollahi says drug development needs the same interactive loop: hypotheses about molecules or pathways tested in-silico against simulated organs and cellular twins, rather than waiting 10-15 years. He cites Google DeepMind's Nobel Prize-winning protein structure work, noting it covers structured molecular data but not the next level, systems biology, such as how rapamycin interacts with the mTOR pathway. He counts about 40 AI drug-discovery startups with 8 billion dollars in funding since 2010 and expects this to grow sharply following the LLM boom of the last three years, alongside a rising number of open healthcare LLMs (such as BioMistral and Meditron) and MCP servers now used for protein structure and clinical decision support.

What needs to change next

Assadollahi calls for four next steps: a meta-framework to link simulations across gene, cell and organ levels; more venture capital to fill gaps in the in-silico tooling landscape; broader access to healthcare insurers' existing patient data; and a legal shift so aging itself, not only named diseases, can be a target for drug registration and personalized medicine, given that current trials and approval processes assume drugs for large, uniform patient populations.

Q&A highlights

Asked whether digital twins predicting lifespan could damage people's joy in living, Assadollahi says there are two open questions: whether the concept of death gives life meaning, noting his own parents chose to let go peacefully, and how social security systems would cope if lifespans broadly doubled. Asked about Germany's electronic patient record, he says new health-data-usage-law initiatives (the exact German term is unintelligible in the transcript) and permission for clinics to use cloud infrastructure are starting to make research access more workable. On ultra-processed food, he explains it is molecularly smaller than whole food, which changes how it moves through the intestines and disrupts the microbiome, and says Europe's food-labeling debates on sugar and fat have been weakened by industry lobbying compared to countries like Singapore. Asked how a digital twin can be built when so little of the brain is understood, he says the Siemens-style twins do not model cognition but reproduce known structural, genetically defined patterns such as neuronal strand organization for pharmacological use, not a full simulation of a person.

Quotes

Ideally I want to die when I want to die.

Ramin Assadollahi

I think we need vibe coding for drugs.

Ramin Assadollahi

This revolution is just ahead of us, it's very very close from my perspective.

Ramin Assadollahi

Questions answered in this talk

What is longevity escape velocity?

According to Ramin Assadollahi at Rise of AI 2025, it means each medical improvement should extend a person's remaining lifespan far enough to reach the next improvement, citing Aubrey de Grey's claim that the first 1,000-year-old may be only about 10 years younger than the first 150-year-old.

Why is drug development so slow and expensive?

Assadollahi states that a new drug costs 400-500 million dollars in the best case and around 2.5 billion dollars once failures are counted, takes 10-15 years, and that fewer than 11% of candidates even reach phase one clinical trials.

What are digital twins in longevity and drug research?

He describes them as computer simulations of human biological systems, such as a Siemens-built cellular-level heart model that needs 12 hours to simulate one heartbeat, and notes only around 16 such digital twins exist as of the talk.

Mentioned

longevity escape velocity, digital twin, in-silico simulation, Model Context Protocol (MCP), microbiome, inflammaging, vibe coding, systems biology, AI Scientist

Keep exploring

More from Ramin Assadollahi

More from Rise of AI Conference 2025

More on Health & Science

Transcript

Auto-generated transcript, not edited. · 5,208 words

Show the full transcript

Wow. Oh, well and here you have technology is not mine obviously. Well, obviously. Thanks. Thanks a lot. So, 29 minutes longevity. Everybody knows what that is. Are you often thinking about your own death? Maybe not. Yeah. Or how to improve your life. So um this is about longevity and the impact of uh AI and uh I'm sure you know all this sentence. We can add days to life but we cannot uh but we can add life to days. And this is by Cesaly Saunders who was the founder of the hospites movement. Um and I personally would love to optimize that a bit saying okay ideally I want to die when I want to die. So uh being limited by my biology and uh you know dying at 60 or 80 um is not the optimal thing for myself uh in terms of a longevity movement and so ideally I want to die when I want to die and if that's 160 then should be it right and uh ideally certainly we want to uh live

happy and healthy and this is uh what the talk is about and um if If you're looking at longevity and I'm not sure how many of you are thinking about longevity or reading things, hands up. Yeah, a bit. Okay. How many of you are eating supplements like like metformine, ropamyine, these things? Okay, that's at least a half. Um, so I'm not going to tell you anything new. Uh, one of the aspects is uh sleep uh physical activity and nutrition uh called span. You can read that in all of the books about blue zones etc. Second thing is supplements. This is how Ray Kurtzvile uh became um very famous because he's eating I think 120 pills per day.

Um I'm not sure whether this is the right way to approach it but um people can do what they want. Uh the third thing is um changing the body um using genetics for example uh blood exchange. So Brian Johnson was changing blood with his son etc. Uh and feces uh transplant which is what I'm not going to touch today. Um and uh finally you certainly could think about uh LLMs taking up all of your knowledge your personality etc and have a silicone copy of yourself. Um this is also not what I'm going to take talk today. So number three, number three, you probably know Aubrey Deg Grrey and um he said the first uh thousand year old is probably just 10 years younger than the first 150 years old.

And for me it's hideoutite. I uh last year I turned 50. So uh if I'm lucky I'm going to live uh another 50 years. and um reaching this um longevity escape velocity uh is the challenge to get within the next 49 years. So every medical improvement that we see should improve my lifespan uh for the next let's say decade so that I can get the next medical improvement and get older and older and old and this is the idea of escape velocity and uh now we're going to look at different aspects in longevity research how uh this can be achieved and uh for me it's four different systems that we need to tackle and certainly you research is covering all sorts of uh different levels and aspects but for me it's these four the genes themselves they define how your body is built then the microbiome everything that you have uh in your guts and on your skin um we have the central nervous system uh of course like Alzheimer's uh etc and um very

important the immune system uh which is kind of a post-processor because everything that is going wrong in your body is tackled by the immune system. So you want to keep that alive. When we're looking at genes, um it's very interesting. There is a lot of literature about uh shared genes that centinarians have. So people that get 100 years old. Uh the interesting thing is um that there is a lot of genes that uh specifically address um the morphology of some organs but others uh also have uh an impact on whether you get Alzheimer's or not. So uh ApoE for example is one of the genes that you can carry and uh you may get Alzheimer's by a higher uh probability and now we're generating this data and we understand that uh 100 year people have genes uh that are better than ours.

How do we transfer this knowledge to for example myself? Uh that's going to be an interesting thing. Second thing is you have about a 100 trillion little living animals in yourself. So you're not alone. You're you're won't you mind shaft? Yeah. Um and a third of them is neutral, a third of them is beneficial and a third of them is competitive. And um you're building up this up during your life. Um but the composition uh of these three is changing over the life. And around 80 years old, the competitive guys that want to use you or your body for their uh life so to speak um are taking over and this is reducing the uh effect of your immune system.

So keeping your gut um healthy like dam macham which is one of the books yeah uh is absolutely uh important and uh we need to understand how to work with your gut. It's not just about gut feelings. Haha. Um, and certainly, uh, I I used to be a neuroscientist, so I looked a lot in into the brain. Uh, my dad passed away, um, with Alzheimer's. I was with him, uh, over seven years. So, I know how the brain is decomposing. The brain is actually really, for everybody of you, even if you stay uh, healthy, is shrinking over the years. So it's getting smaller and you're losing connections. Uh and the energy consumption, how the brain cells are producing energy is also going low.

And the problem is that many of these um diseases that we have like Alzheimer's uh are partially interpreted as also an immune system thing like your brain has inflammation and you want to fight that. So the immune system seems to be one of the four uh most important things and this is from a study that um tries to tackle all of these uh compositions how aging is actually happening. Uh and there is uh one sentence I think a European guy invented that is inflammaging. So the more inflammation you have in your body, uh the easier you get older and your organs will get older and so on. So one of the super important things is to keep your immune system trained um and well established.

Uh and that's I think one of the most important aspects and the immune system of course like the uh microbiome is a super complex system. It's not like an organ like the liver or something like that but it's really hard to understand. Um and when we're looking at how are we tackling this then the standard problem that we have in the pharma industry for example is that it's super expensive. So it costs you even in the best case about 4 to 500 million to develop a a new drug. But if you factor in all of the fails that you have during that journey, then you're easily uh around two and a half billion um per medicine and it's taking you about 10 to 15 years.

I don't have uh time for that and this is all uh without AI, right? So the clinical trials are uh also broken on a different level like um you need to find the right kind of patients that fit basically to uh the the pharmacological mechanisms that you're looking for. And the second thing is um since everybody is different uh you will have subgroups. So you may not see the right kind of effects uh basically even if you're doing the uh these studies clinical studies. And this means that uh only less than 11% uh even reach phase one and you have as we've shown here uh you have three phases that you need to survive. So it's super expensive because even if you just add um the lower uh parts here it's super expensive to do these experiments.

So we as a AI community would say okay uh LLM AI let's go. Yeah. Why are you still cooking molecules? Ridiculous. And um I would guess that everybody of you knows the AI scientists. It's a publication in a GitHub repo that can generate ideas, experiment them in silication on a human level. Um this is the second version uh that was published just recently like three weeks ago or something. Um and you could ask yourself, hey, why are we not using this to uh develop new drugs? And the problem is that these experiments and the update plan is not happening in biology because you cannot still entirely simulate biology. And so what I would love to do is in silicico uh experiments, longevity experiments in the computer.

Um if you're looking at uh how many simulations we have in the body um or for the body uh the problem is we need a human that is fully described on various levels like the genes and the molecules and uh the organs and the immune system and so on. Plus uh ideally if you have that model of a general human so like we are having a model of a general genome then you can uh use the parameters of a single pat patient and say this is your genome and this is your biological data and we are doing a parameterization of this model so that we reflect you and develop a medication exactly for you. And now let's look at how many digital twins we have.

And the digital twin um revolution kind of it's not really just started in 2015 and actually we have 16 digital twins uh at as of today. So it's not too many and if I were Dell or HP or Nvidia then I would definitely invest in this area. uh and there is for example the heart model uh I think uh was developed by Zemens and it takes about 12 hours computation time to let the heartbeat once but it's a full like cell level uh simulation of a human heart. So it's super interesting um a lots of literature if you get the paper you will have links to the immune system and what effects they can do with the immune system microbiome and so on.

So it's really simulations that we can use. A second thing is for getting the parameters to uh actually use your simulation with your genes. Uh there is a second good news. So um I did some research on how many uh sequences we did and how what the cost is and the cost is going dramatically down for uh sequencing your own genome. It's about 400 bucks. Uh with these 400 bucks you get 150 reports about uh all of your genetic dis predispositions of uh all sorts of diseases that you could get. It's quite interesting I think. Second thing is we need fast data. So on the right hand side you see a startup that we just reviewed um in an angel club in in Switzerland, Brainscape.

This is an EEG. It's recording your um brain activity, but you can implant uh that below your skin. So, it's a full-time 24/7 EEG that is walking with you and you're grabbing the brain uh data um 24/7. Super interesting. Um and then there is the Dexcom aura uh fusion that we were just talking about yesterday which means your ring and uh your uh glucose monitor will talk to each other and pull the data. Second thing is I think also super interesting flow bio but there is a couple of more um different devices that can record your sweat. Your sweat is uh basically showing all of your metabolites from your body. So everything that you do is um kind of detectable in a sweat and there is a sensor that um you can buy today uh to generate that data and so prevention works.

There is a lot of um studies that show that for example uh recording the ECG in a clinic you can save a lot of lives not just by looking at the data but really having an AI that is looking at the recorded data live and is uh basically alerting the nurses to uh to save lives which is um I think one of the most important things. So vibe coding I guess that everybody tried it out uh in the last couple of weeks. Yeah. Um so but when we are stepping back uh one step and saying okay what is VIP coding in an abstract way we have three things. One is the soft part which is my ideas or user requirements or ideas uh etc.

Then you have kind of the moderator which is bold or cursor or uh replet etc which is the software that is generating software for you. Um but these softwares can also record screens understand error messages etc. And then you have the rigid part which is uh you know how Python is spelled syntactically what is a definition of an API what is a structure of database this is rigid. So the LLM has to work with the uh generated code against rigid data and that's I think a very important part which will improve over time. What does that mean? I think we need vibe coding for drugs. So uh we need the same for drug development. I want to have interactive drug development uh in the future.

This would be kind of the speed of my thinking. I want to talk to a machine and explore ideas interactively instead of waiting 15 years. So how would we get there? Hypothesis are generated by molecules that you have in mind or pathways or you know mechanical systems uh uh that you have on cell level. Uh you certainly have LLMs already that are thinking in proteins for example. Uh you can do incilico testing. This is nothing new. I didn't invent that but I think that uh in this setup it would be super interactive and certainly you have models that you developed about uh organs etc. And this rigid part would be you know simulated organs uh systems biology uh uh cellular twins and so on.

And um again there is a company that we all know Google or DeepMind and they won the Nobel Prize and that's correct to do so because on the left hand side you have the structured data already. In the middle you have the LLMs uh or the transformers and on the right hand side again you have structured data which is verifying the molecular structure of uh uh the proteins that they invented. So there is the mechanic in place. However the proteome is just one level. The next level that we need to see is the systems biology level which means um you know if you're uh eating rapamy etc. This is uh basically one part of the system in your body that works with the mTor malian um target of rapamy.

So this is actually how it works and we need to bring that into the computer in a simulation on a cell level so that we really can simulate interactions with molecules and um I also did some research on AI drug developers because you would say uh this is the next thing that we need to do naturally and then the screen uh got blank and I didn't know what I talk about but um you see here we have about 40 startups which is not entirely an explosion from my perspective and 8 billion in funding is also not uh you know too much capital allocated but you also see they started in 2010 and we had the LLM revolution like um let's say three years ago or something so I would expect that this number is really going up uh in the next couple of years and this is why I say that this revolution is just ahead of us it's it's very very close from my perspective.

Okay. So for everybody who wants to try out things, I also collected a couple of uh large language models, open source um um biomistral for example is a 7 billion u parameter model that runs on my computer at home, but there is also meditron I think that's made by Nvidia um and a couple of others that uh are also trained on different uh aspects of healthcare. And then um who is using MCP's model context uh protocol servers two okay seven eight um it's super interesting they were introduced uh last November and we have five months in in 2025 and these are the M MCPS already in healthcare I think that's tremendous because this is exactly the structured data that you want to have to interact with the LLMs and there is a lot of things going on uh I just um took the protein structure as well as uh clinical guidance for decision support that is basically plugging into uh healthcare LLMs super um inspiring from my perspective.

So towards um personal medicine from my perspective AI has revolutionized uh already the protein synthesis. We have 200 billion simulated proteins already by Google that we can use. That's an explosion in in terms of productivity. But now we need to enter the systems biology and then finally we can uh build up models that we uh can use with personal data. But if we reach that then we also need to change the whole legislation and how we approve drugs because drugs are al always usually working on on 3,000 patients etc. And if you're doing a personal drug then the whole registration procedure is wrong. Uh very similar to medtech companies that we have right now. I mean you're developing some AI algorithm in a hardware and you want to register that and it takes I don't know five years and during that time the whole machine learning paradigm has changed.

So we need to change also how we as a community are looking at uh the technology to be used by um uh whole sets of people. So from my perspective it's just the beginning. Um and I would think that we need again four uh next steps. Namely um we need to not only explode the number of simulations but we need to have a meta kind of framework where we plug in the different levels of simulations like you have a cell level you have a gene level uh you have a an organ level etc. And you need to have a kind of a meta structure where you say okay here is a simulation that I have here is a simulation that I need and I can use that in a cascaded measure.

We don't have that right now and I think uh at least according to my research there is a lot of white spots in the tooling landscape um to get into incilico uh simulation uh on various levels. We need to find these white spots and fill them with venture capital money. And um certainly as always in an AI paradigm, we need more data for the community. Of course, I've been working a lot with um healthcare insurers, for example. We have a lot of data. We're just not allowed to use it. And so that's another discussion that we had. is is it if you're not using patient data to make the patient uh healthy again. So this is a paradigm uh that needs to shift.

Uh same is true for aging. Um a lot of drugs cannot be tested in the classical paradigm of uh clinical tests because clinical tests are only allowed for diseases that you have. So if aging is not a disease, I cannot even enter the process of registering a molecule uh against aging. So these are the four things that I would advise for today. And I'm actually three minutes faster than I thought. Yes. Thank you. That's fantastic. Do we have questions from the audience? And yes, I saw your hand first. I know there was a a lady at the heater next to you uh at at the wall. Yes. Thank you. Um I have a very tough question.

Um if uh we uh can overcome all the hurdles and get digital twins of ourselves like profiled digital twins and uh we would then measure how long we would live. Wouldn't that change completely our social behavior because we would try to combat illnesses that are predicted? We would lose or that would completely destroy and kill the joy in our lives to live it to the fullest extent because we would fear that oh I have two or three free years to go. So um is there um an answer or are there already researches in in this regard how that would change? I I think there is there is two aspects to this. Uh one is um is there value in the concept of death so that you live your life differently because you know that it's going to be over and will this uh philosophy change if you know you know I can live as long as I want.

I had the luck uh to have two parents that said to me it's enough. I'm 87 now and I want to go. I mean one was Alzheimer's but still he was happy and I think leaving this earth happily that should be the the point no matter how we um achieve that. So that's one aspect. The second aspect is uh social security systems. So uh if we choose and the technology yes I know Jeff Bezos and so on all of these guys uh will profit from this uh certainly faster than we do but if the application is exploding then we have a lot of problems like um overpopulation which certainly translate to something else instead of saying okay the Germans are 83 millions and now they are 85 what will happen if everybody is doubling their their age that they can achieve.

So these are I think the two questions that we need to tackle. But before that I think we should invest in uh you know this kind of technology. Thank you. You first and then Katina. Um I have two questions if I may. You mentioned that glucose ma this I think was Dexcom. Yeah. It's not available in Germany isn't it? I think it's only in the US. I actually don't know. I was able to order one. Okay. Okay. Because I checked it last week and they said it's only for the US. Okay. But the other question I'm not a fan of the electronic patient file system in Germany because it's fairly unsafe concept or of No, the concept I'm fine with but the implementation is crappy.

Yeah. Um but that would make access to patient data for research and for development of new health products actually a lot easier. Is that true? Yeah. Yeah. I as far as I understood the last Mr. Um they were implementing the gizont not gazettes never write and invent a German word u below 15 letters. Uh and so there is a lot of these um initiatives that are coming up uh so that we are not only establishing an electronic p patient record but actually really use it. For example, clinics are also now uh allowed to use the cloud in certain circumstances. So, it's also about infrastructure, right? If I cannot access the data, then all of that machine learning stuff is not worthwhile.

Please, I mean, beautiful talk. I really enjoyed it so much. Thank you so much. Um, I'm a huge fan of longevity and most recently I was unlucky spending several weeks at the HNO hospital. um at no hospital and 80% of my co-patients were there caused by their lifestyle they have chosen. So drugs, nicotine, uh and very specific sports they've chosen to do. Yeah. Um how can So this is human behavior based. Yeah. uh what are there any existing fruitful approaches combining the AI approaches regarding drug development and changing human behavior because we do know that the maj the major reason why people die earlier today in the western countries is caused by the lifestyles they have chosen eating behavior nicotine etc.

Yeah, absolutely. Absolutely. If you're looking at the top four, it's diabetes and heart diseases and brain, etc. And lots of them um are correlated with uh just being overeating. Let's let's let's put it this way. And it's a it's a really interesting part because certainly we need to change that and it's another philosophical question like are we as a society allowed to take that freedom from people uh who choose their lifestyle as they do it's also an insurance uh system question like you are doing this kind of risky sports why should I pay for that you're uh taking nicotine why should I pay for that So uh this is another discussion that we need to have from my perspective.

And so um on the other hand drug development is kind of mitigating some of the risks like uh ompic and all of the GLP1 uh antagonists. It's quite interesting. Now you have a drug uh that you can use because you're overweight. Yeah. So is that freeing you from uh doing sports or shouldn't we use that because you you know should uh lose weight etc. It's another discussion that is coming up. We have one question here in the first row. Oh sorry do do you wanted to make a comment? No thank you so much. Thank you. Thank you. Um the microphone here in the first row and we have a minute left. Also I also have one question and what is your opinion about the freedom of the industry to produce this industry food which also causes uh diabetes and so on.

Any thoughts on that? The only thing that I know is uh an interesting fact because I was asking myself why is ultrarocessed food uh unhealthy you puffs and the interesting thing is ultrarocessed food is molecularly smaller than uh the stuff that you're eating when you're you know biting into a cucumber or something. And so how it travels through your intestines is different. um because uh the molecules are too small and so the microbiome is distributed differently in your gut um so that some of your pre-processors so to speak don't see the molecules that you're eating. So we know why it's unhealthy but there certainly there is industry there is capitalism I don't want to sound too left but people are producing things that other people are buying so is it my responsibility to say no you shouldn't do that I don't know uh certainly I'm I'm looking at the um at the traffic lights that we had here in Europe uh about fat and sugar and so on and Europe was too weak to say

hey industry less sugar we want the real numbers on on the packages etc. So we can do things but obviously the politics or I don't know people who make the rules um might be influenced too much u by some lobbyists and then do you go to Singapore and there they have less sugar in the soft drinks and you wonder why yeah yeah it's quite interesting there is um font lemon uh and the the level of sugar is varying across the different countries within Europe even within Europe. I have two thoughts that lead to one question. So first is um Bruce Lipton, one of the first biologists said it's not survivor of the fittest, it's survivor of the fittest team.

So he said 100 billion cells work together. Then I know uh from neuroscience we barely know our brain. So both lead me to the question, how can I make a digital twin out of these of organs out of the whole body if we don't know? Yeah, I think it's it's um you know I was also puzzled when I saw that they replicated the brain like okay well um but the reality is of course what do you want to reflect in a jigital twin so is it the uptake of um some kind of molecules against Alzheimer's is it uh the amount of blood flow that is going uh in different directions and so on so they are not simulating a person or how you are thinking but they are using for example the structure of how the neuronal um strands are organized in your brain because this is repeated and it's also defined by genetics and so this is the part that they are reflecting for pharmacology etc.

they are not copying a person. But wouldn't that just isolate one part and it could go this way because we um yeah we looked into that but it could go a totally different way because there are 90% of the brain that we didn't look at in that scenario. Yes. I mean looking at the human brain, I actually did my PhD in in parts in tubingan where they started to actually count uh different neuronal cells in cell tissue and it took them I don't know 20 years to to get less than a um cubic millimeter of of the brain to to be mapped and the technology has changed so you can stain things and so on.

Um but the the question is if you know the structure of the brain, what kind of information in terms of application can you draw from that? If I know the the you know the the streets of Germany, you still have to have a car and a goal where you want to go instead of just knowing where the streets are, right? And so I think it's an interactive thing, but the interesting thing is that most of the digital twins that I found were actually just once. So there is one group that is producing a heart. There is not five different labs competing and so on. So it's really early stage in in the simulation. Okay. Well then we'll see where that leads leads with all the uh technology that we heard today that it becomes more efficient and more accurate and maybe then doesn't need another 10 years until we have precise digital twins.

Thank you. Thanks.

Rise of AI 2027 · Berlin · May 2027

Be in the room for the next one.

Ten years of talks started as conversations in one curated room in Berlin. The next edition brings 300 selected leaders together in May 2027.